Clinical Trial Update: Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD [Phase 4]

View source ↗

Summary

This document reports the completion of a Phase 4 clinical trial evaluating a combination therapy of daclizumab and infliximab for steroid-refractory acute graf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Remicade (infliximab)
• Zenapax (daclizumab)

Snippet

Sponsor: University of Iowa | Conditions: Graft vs Host Disease | Phase 4 | Status: COMPLETED